Patent laws for life forms, particularly genes, have been hit by numerous controversies despite thousands of patents already being granted in major patenting jurisdictions such as the US, Europe and Japan. The grant of patents on human genes has elicited serious apprehension in view of associated legal, ethical, moral and political sensitivities. With courts, legislatures and patent offices the world over reacting to such developments, the only constant in gene patent jurisprudence is change.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.
30 June 2026 Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.
25 June 2026 The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.